You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

~ Buy the RECARBRIO (cilastatin sodium; imipenem; relebactam) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR RECARBRIO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for RECARBRIO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04493151 ↗ Imipenem/Cilastatin/Relebactam PK in ECMO Recruiting Merck Sharp & Dohme Corp. Phase 1 2021-01-01 Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO.
NCT04493151 ↗ Imipenem/Cilastatin/Relebactam PK in ECMO Recruiting Joseph L. Kuti, PharmD Phase 1 2021-01-01 Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO.
NCT04785924 ↗ Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Recruiting Merck Sharp & Dohme Corp. Phase 4 2021-06-07 This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital. The objectives of the study are to demonstrate successful treatment of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use at the same institution.
NCT04785924 ↗ Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Recruiting Atrium Health Phase 4 2021-06-07 This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital. The objectives of the study are to demonstrate successful treatment of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use at the same institution.
NCT05146154 ↗ Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients Not yet recruiting Merck Sharp & Dohme Corp. Phase 4 2022-01-01 This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RECARBRIO

Condition Name

Condition Name for RECARBRIO
Intervention Trials
Sepsis 1
Antibiotic Resistant Infection 1
Carbapenem-Resistant Enterobacteriaceae Infection 1
Critical Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for RECARBRIO
Intervention Trials
Pneumonia, Bacterial 2
Communicable Diseases 1
Obesity 1
Bacterial Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for RECARBRIO

Trials by Country

Trials by Country for RECARBRIO
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for RECARBRIO
Location Trials
Connecticut 2
Texas 1
Pennsylvania 1
Indiana 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for RECARBRIO

Clinical Trial Phase

Clinical Trial Phase for RECARBRIO
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for RECARBRIO
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RECARBRIO

Sponsor Name

Sponsor Name for RECARBRIO
Sponsor Trials
Merck Sharp & Dohme Corp. 3
Q2 Solutions 1
St. Christopher's Hospital for Children 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for RECARBRIO
Sponsor Trials
Other 10
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.